Company Revenue

U.S. spinal sales drove Orthofix's sequential improvement in 3Q20 but were not enough to overcome lingering procedure volume declines due...

The company grew +2.9% in 3Q20 as it begins a new phase of its strategic transformation that includes focus on...

The company grew +41% in 3Q20, driven by a record-breaking September. ATEC sees itself as well-positioned to take share from...

While the company's orthobiologics business remains impacted by COVID, gains from joint preservation and restoration products offset the losses....

The company declined -6.8% in 3Q20, as it remains impacted by the slower recovery of primary arthroplasty surgeries compared to...

The company grew nearly 26% for 3Q20, driven by continuing favorable coverage policies in the U.S. and backlogged procedures in...

The company grew +1.5% in 3Q20. While spine surgery volume is approaching pre-COVID levels, the company does not expect overall...

The progressive return of elective procedures and demand for Mako drove the company’s V-shaped recovery from the second quarter pandemic...

While the company improved sequentially, weakness in emerging markets, and significant knee replacement losses hobbled its recovery....

The company grew its soon to be divested orthopedic franchise +5.1% in 3Q20 as momentum from backlogged procedures carried into...